Hassabis on AI for Drug Discovery
Chris_Armstrong · x · 2026-07-13
Demis Hassabis believes one of the most vital applications of AI is helping cure a massive number of diseases.
He emphasizes that Isomorphic Labs isn't about building chatbots, but rather accelerating the entire drug discovery pipeline: making the path from predicting molecular properties to clinical trials faster and more efficient. Because models can better predict the properties of candidate drugs, they are more likely to pass these trials. Hassabis notes this capability offers enormous social value and could spawn a "hundreds of billions of dollars" commercial opportunity.
The core takeaway: the true value of AI in health lies not in another chatbot assistant, but in compressing drug discovery cycles and translating that speed into commercial returns.
More from Research
- Stanford Data-Centric AI Workshop reopens site, extends poster deadline — jure · 2026-10-26
- 'Vibe verification': ~60% of AI-written formal specs prove the wrong property — basedjensen · 2026-10-26
- Ito: a browser that detects browsing intent and auto-organizes tabs into Flows — andrewkuznet · 2026-10-26
- Cornell study says brains process language as linear sequences, challenging Chomsky's hierarchy — anirbanbandyo · 2026-10-26
- Hi3D V1.0 open-sourced with 2M training assets and 90% slicing success rate — kimmonismus · 2026-10-26
- Ortet evaluates 34 open-weight models on 50 health tasks, finds general leaderboards insufficient — elmanmansimov · 2026-10-26